Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) Treated 15 Months

NCT05092841 is registered in ClinicalTrials.gov with Tasly GeneNet Pharmaceuticals Co., Ltd as lead sponsor.

NCT NCT05092841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05092841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) Treated 15 Months
Lead sponsor
Tasly GeneNet Pharmaceuticals Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
September 28, 2021
Completion date
March 18, 2024
Enrollment
176 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

charcot-marie-tooth type 1a